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fd. Note - This overview was originally presented at the 
International Symposium on Clinical Disorders of Bone 
and Mineral Metabolism, May 9-13, 1983. The following 
list indicates the presentations given in this session at the 
Symposium and the contents ofthe corresponding chap-
ter in the Proceedings of the Symposium published by 
Excerpta Medica. The numbers in parentheses refer to 
pages in this volume. Complete information about the 
contents of the Proceedings can be found at the back of 
this issue. 
The surgical management of patients with primary hyper-
parathyroidism. S.A. Wells Jr and G.S. Leight (152) 
Is parathyroidectomy of benefit in primary hyperparathy-
roidism? S. Posen, P. Cl i f ton-Bl igh, T.S. Reeve, C. Wag-
staffe, and M. Wilkinson (154) 
Medical approaches to the management of primary 
hyperparathyroidism. J.P. Bilezikian (159) 
fstrogen therapy for postmenopausal women with primary 
hyperparathyroidism. R. Marcus, P. Madvig, M. Crim, J. 
Kosek, and A. Pont (162) 
I n the hands of a skilled parathyroid surgeon, parathy-
roidectomy (PTX) is a curative procedure for primary 
hyperparathyroidism (PHPT) more than 95% of the time. 
Why then do we need to discuss the management of 
PHPT further? Why are not all patients whose diagnosis is 
firmly established on clinical and biochemical grounds 
sent to a skilled parathyroid surgeon for elective PTX? 
The questions that remain are really philosophical: What 
is meant by " c u r e " of PHPT? Which patients with PHPT 
have a disease that needs a "cure"? 
During the past two decades, many patients with PHPT 
have had the diagnosis considered because of a chance 
f inding of hypercalcemia on a biochemical screen, per-
formed either as a routine measure in a well patient or as 
a screening test ordered for other reasons in an ill 
patient. Today, most patients with PHPT present in this 
way, rather than as the more classic patient wi th "stones, 
bones and abdominal groans." 
Most consultants to whom patients with PHPT are referred 
develop arbitrary criteria that mandate PTX at the time of 
diagnosis. These include signs or symptoms directly re-
ferable to hypercalcemia, nephrolithiasis, skeletal dis-
ease, peptic ulcer disease, pancreatitis, or impaired renal 
function. Most physicians have a limit point for hyper-
calcemia above which all patients are referred for PTX. 
While this arbitrary criterion varies among physicians, 
most accept a limit of 11.5 to 12.0 mg/d l . 
In the now-classic study conducted at the Mayo Clinic 
(1), a large number of patients with asymptomatic PHPT 
was fol lowed prospectively up to 10 years after the initial 
diagnosis. Twenty percent of the patients were lost to 
fo l low-up dur ingthe observation per iod, and 20% of the 
patients had progression of the disease so that PTX was 
indicated. In retrospect, it was apparent that a substantial 
number of patients in whom the disease was considered 
to have progressed were initially misclassified and that 
the rate of progressive disease may be less than that 
which was observed. A defect in the study design was the 
failure to assess the effect of successful PTX on the natu-
ral history of the disease. In addit ion, this study was 
undertaken before sophisticated techniques for measur-
ing bone mass (and the effect of PTH excess on bone 
mass) were available. These problems were addressed by 
two papers in this section of the Symposium. 
Thefirst of these, by Posen and his colleagues (pp. 154ff.), 
was a retrospective analysis of 128 cases which were 
reviewed an average of 7.8 years after "successful" PTX. 
This study provided some surprising and challenging 
observations. Although 15% of the patients had died dur-
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ing the fol low-up period, death could be attributed to 
surgery in only one case. Whether the death rate reflects 
the fact that prevalence of PHPT increases with age or 
whether PHPT contributed to irreversible deterioration 
in function before surgery could not be ascertained from 
this study. In contrast to other studies, PTX did not appear 
to have an entirely protective effect against the develop-
ment of nephrolithiasis. No patient who was free of 
stones before PTX developed stones during the postop-
erative fo l low-up. However, in the 70% of patients who 
had nephrolithiasis before surgery, no significant reduc-
t ion occurred in the number of patients who developed 
recurrent stones. Successful PTX did not havean appreci-
able effect on hypertension present in 40-50% of the 
patients, nor did it restore impaired renal function. Using 
crude radiographic assessment, the authors found no 
improvement in the prevalence or degree of osteo-
porosis after PTX. 
Neer and his colleagues from the Massachusetts General 
Hospital presented similar observations on 45 patients 
fol lowed prospectively for three years after successful 
PTX. These patients all had mi ld, asymptomatic PHPT 
before surgery. The decision to operate was based on the 
presenceof impaired renal function or, more frequently, 
on the presence of osteopenia (bone mineral content 
more than two standard deviations below expected for 
age, sex, and race). Two patients developed kidney 
stones dur ing the fo l low-up period. As a group, there 
was no improvement in blood pressure or in renal func-
t ion, nor was there any restoration of the deficit in bone 
mineral content. Perhaps of greater importance was the 
failure of PTX to slow the rate of bone loss when the 
group was considered as a whole, although such decel-
eration was observed in some patients. 
Posen, et al also reported findings in 32 patients who 
were observed for an average of 6.6 years after unsuc-
cessful neck exploration for PHPT. There were four 
deaths in this group (12.5%), one of which resulted f rom 
progressive vertebral fractures and respiratory failure, 
presumably a manifestation of progressive osteitis fibrosa. 
As was the case with the successfully treated patients, 
kidney stones did not occur in those patients who were 
free of stones preoperatively. They found no other evi-
dence for progression of PHPT. 
A noteworthy and challenging observation was the 
seemingly high prevalence of nonparathyroid malig-
nancy in those patients who remained hypercalcemic 
after surgery. In the successfully treated group, eight of 
128 (6%) developed a variety of malignancies. However, 
seven of the unsuccessfully treated group (22%) devel-
oped malignancy (p<0.01). There have been several 
reports of increased prevalence of nonparathyroid malig-
nancy in PHPT when compared to the general popula-
t ion, but it has never been clearly established whether 
this is more than the chance occurrence of two relatively 
common conditions in an aging populat ion. The obser-
vation by Posen, et al focuses attention on this potential 
"compl ica t ion" of PHPT. If hypercalcemia, elevated PTH 
levels, or perhaps PHPT itself is in some way "m i t o -
genic," it is surprising that evidence for this fact was not 
found in the 10-year prospective study at the Mayo 
C! inic. The prevalence of malignancy in a separate group 
of 74 patients who did not have surgery is not known but 
would be of interest. 
If successful PTX is without obvious benefit in patients 
with mild PHPT, has anything new been learned since 
the Mayo Clinic study of patients who were not oper-
ated? Neer and his colleagues reported their three-year 
study of a small number of such patients. Like the Mayo 
Clinic experience, the drop-out rate was relatively high 
(12%), an occurrence which must be carefully consid-
ered whenever a decision to fol low a patient with PHPT is 
undertaken. During a three-year per iod, the Boston 
group detected no significant progression o f the disease, 
as evidenced by serum calcium and inorganic phosphate 
levels, urine calcium excretion, renal funct ion, and bone 
mineral content. Several anecdotal reports exist of 
patients with established mild PHPT who developed 
sudden marked rises in serum calcium while under 
observation. Since at present no way of predicting this 
rare, l i fe-threatening compl icat ion is known, every 
attempt must be made to ensure continuous observation 
of all patients with PHPT who do not undergo elective 
PTX at the time of initial diagnosis. 
Wells and Leight (pp.152 ff.) described the type of surgery 
required for patients with PHPT, highlighting their expe-
riences at Duke University in North Carolina and Wash-
ington University in St. Louis. Most surgeons prefer to 
identify all four parathyroid glands at the time of initial 
neck exploration. The surgeon should rely on his or her 
own skill at identifying parathyroid tissue and resect those 
glands that appear macroscopically enlarged (>50 mg). At 
the time of surgery, the role of the pathologist is to con-
f irm that resected tissue is indeed parathyroid, and the 
surgeon should not rely on the descriptive terms "para-
thyroid adenoma" and "parathyroid hyperplasia". 
Of 350 patients observed over a five-year per iod, 68% 
had a single enlarged gland, 22% had two or three 
enlarged glands, and 10% had four enlarged glands. Dur-
ing a four-year fo l low-up, PHPT did not recur in any 
patient with single gland enlargement and recurred in 
only one patient with two or three gland enlargement. 
207 
Kleerekoper 
Patients with four gland enlargement have been man-
aged by total parathyroidectomy and autotransplanta-
t ion of tissue in the forearm muscle. The incidence of 
graft failure was lessthan 5%. Of patients with fourgland 
enlargement, 36% had familial hyperparathyroidism. 
The incidence of recurrent hypercalcemia in patients 
with four gland enlargement without familial hyperpara-
thyroidism was 15%. 
There remains a group of patients with PHPT in whom 
elective surgery would normally be recommended, but 
because of other medical considerations they are at too 
great a risk for elective surgery. There is also a growing 
group of patients for whom surgery is recommended but 
who decline surgical intervention. Bilezikian (pp.159ff.) 
f rom Columbia University outl ined medical alternatives 
for these patients. General principles of management 
include maintaining adequate hydration and avoiding 
immobil ization and thiazide diuretics. There is l imited 
evidence that restriction of dietary calcium is of benefit. 
However, if one demonstrates increased intestinal absorp-
t ion of calcium or elevated 1-25 dihydroxy cholecalci-
ferol levels, dietary restriction of calcium might be 
beneficial. 
Drug therapy to inhibit parathyroid secretion (e.g., beta-
adrenergic-blockade and histamine receptor antago-
nists) or to inhibit the action of PTH on bone (e.g., estro-
gens, calcitonin, diphosphonates) has not been helpful 
in most centers. However, scattered case reports exist of 
a short-term reduction in serum calcium with some of 
these drugs. Estrogens have the most potential benefit, 
particularly in postmenopausal women with PHPT. While 
the serum calcium may not be normalized by administra-
t ion of estrogen, the rate of bone loss may be decreased. 
Summary and Conclusions 
If performed by a skilled parathyroid surgeon, elective 
parathyroidectomy is a simple, safe, and effective means 
of curing PHPT in more than 95% of cases. No equally 
effective medical therapy exists for this disease, although 
the administration of estrogens to postmenopausal 
women with PHPT holds promise of decreasing the rate 
of bone loss. Many patients, perhaps the majority, derive 
no clinical benefit f rom having their disease " c u r e d " by 
PTX. What is not currently available from the data, either 
in the published literature or in the material presented at 
this Symposium, is the means to predict accurately at the 
t ime of diagnosis which patient is likely to develop com-
plications if not cured. To the classic list of "stones, 
bones, and abdominal groans" that complicates PHPT 
must be added a possible increased occurrence of non-
parathyroid malignancy in untreated patients. If close 
observation dur ing fo l low-up after diagnosis can be 
assured, only a small number of patients wil l develop 
major complications (such as l ife-threatening hyper-
calcemia) if left untreated. Careful observation must 
remain an important caveat, since two prospective stu-
dies have documented a 12% and 20% drop-out rate 
during three and 10-year fol low-up periods, respectively. 
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